Document Detail


Amlodipine: a randomized, blinded clinical trial in 9 cats with systemic hypertension.
MedLine Citation:
PMID:  9595376     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The efficacy of amlodipine (AML) was tested in hypertensive cats in a placebo-controlled, randomized, blinded clinical trial. Five cats were randomized to receive 0.625 mg AML once daily and 4 cats to receive placebo (PLA) once daily. The average systolic blood pressure (SBP) recorded by the Doppler method on day 0 was 212 +/- 21 mm Hg in the AML group and 216 +/- 32 mm Hg in the PLA group. On day 7, the cats receiving AML had a significantly lower average daily SBP (160 +/- 30 mm Hg) but SBP in the PLA group was unchanged (207 +/- 31 mm Hg). On day 7, all cats receiving PLA and one cat receiving AML were crossed over to the other group because of inadequate response. Blood pressure did not decrease adequately in 3 cats by day 14 (7 days of PLA and 7 days AML) and the treatment code was broken. Each of these cats was subsequently administered 1.25 mg AML daily. Cats requiring 1.25 mg AML once daily (6.1 kg +/- 0.7 kg) weighed significantly more than cats that responded to 0.625 mg AML once daily (4.1 +/- 0.7 kg). The average daily SBP recorded in the 6 cats that completed the study was significantly lower after 16 weeks of treatment (152 +/- 14 mm Hg) compared to day 0 (221 +/- 24 mm Hg). Three cats were euthanized before completion of the study. All 3 cats were responders to AML on day 7. SBPs measured 24 hours after AML administration were similar to the average daily SBP, suggesting that AML effectively controlled SBP for a 24-hour period. AML was shown to be an effective once-daily antihypertensive agent when administered to cats at a dosage of 0.18 +/- 0.03 mg/kg sid.
Authors:
P S Snyder
Related Documents :
2806716 - General practice data derived tolerability assessment of antihypertensive drugs.
25060736 - A preliminary trial of the sedation induced by intranasal administration of midazolam a...
11847546 - Ace inhibitors as first-line treatment agents: a comparative study of trandolapril and ...
10454446 - Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. ...
1394696 - Novel uracil derivatives: newly synthesized centrally acting agents.
18830866 - Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of veterinary internal medicine / American College of Veterinary Internal Medicine     Volume:  12     ISSN:  0891-6640     ISO Abbreviation:  J. Vet. Intern. Med.     Publication Date:    1998 May-Jun
Date Detail:
Created Date:  1998-07-13     Completed Date:  1998-07-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8708660     Medline TA:  J Vet Intern Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  157-62     Citation Subset:  IM    
Affiliation:
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville 32610-0126, USA. snyder@mail.vetmed.ufl.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amlodipine / therapeutic use*
Animals
Antihypertensive Agents / therapeutic use*
Blood Pressure / drug effects
Body Weight
Cat Diseases*
Cats
Double-Blind Method
Hypertension / drug therapy,  veterinary*
Placebos
Time Factors
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Placebos; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A syndrome resembling idiopathic noncirrhotic portal hypertension in 4 young Doberman pinschers.
Next Document:  Pulmonary eosinophilia associated with increased airway responsiveness in young racing horses.